阿替利珠单抗联合EP方案治疗广泛期小细胞肺癌患者的效果观察

Efficacy of atirizumab combined with etoposide and cisplatin regimen in patients with extensive stage small cell lung cancer

目的:探讨阿替利珠单抗联合依托泊苷+顺铂(EP)方案治疗广泛期小细胞肺癌(ES-SCLC)的效果。方法:选取ES-SCLC患者98例,按照随机数字表法分为对照组和观察组,每组各49例。对照组采用EP方案治疗,观察组采用阿替利珠单抗联合EP方案治疗。对比两组疗效、治疗前、治疗4个周期后卡氏评分(KPS)、血清肿瘤标志物水平[糖类抗原125(CA125)、糖类癌抗原199(CA199)、癌胚抗原(CEA)]、不良反应及药物经济学分析[成本和效果之比(C/E)]。结果:观察组总有效率、疾病控制率高于对照组(P<0.05);治疗4个周期后观察组KPS评分高于对照组(P<0.05);治疗4个周期后观察组血清CA125、CEA、CA199水平均低于对照组(P<0.05);两组不良反应比较差异无统计学意义(P>0.05);观察组C/E明显高于对照组(P<0.05)。结论:阿替利珠单抗联合EP方案治疗ES-SCLC效果显著,能改善体力功能状况,降低血清肿瘤标志物,安全性高。

Objective: To investigate the effects of atirizumab combined with etoposide and cisplatin(EP)regimen in patients with extensive stage small cell lung cancer. Methods: 98 patients with extensive stage small cell lung cancer(ES-SCLC)were randomized into 2 groups, each with 49 cases. The control group were treated with EP regimen, while the observation group adopted atirizumab combined with EP regimen. Then, the clinical efficacy, KPS score before treatment and 4 weeks after treatment, serum tumor marker levels(CA 125, CA199 and CEA), ratio of adverse reactions and pharmacoeconomic analysis [cost-effectiveness ratio(C/E)] were compared between both groups. Results: The total effective rate and disease control rate was higher than that of the control group(P<0.05);4 weeks after treatment, KPS score was higher than that of control group(P<0.05);levels of CA 125, CA199 and CEA were lower than those of the control group(P<0.05);there was no statistical difference of the adverse reactions(P>0.05);and C/E of the observation group was significantly higher(P<0.05). Conclusion: atirizumab combined with EP regimen has obvious effects on patients with ES-SCLC, which can improve physical function and reduce serum tumor markers of patients. Besides, it is of high safety.